




December 2006

MEDICALTHERAPIES 

Disclaimer

Except for historical information, this presentation may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Who We Are



- © Low risk small molecules: metallo-NSAIDs
 - Metallo-NSAIDs are metal complexes of non-steroidal anti-inflammatory drugs using metals such as copper, zinc, and vanadium.
- © Leading scientists & patent-protected IP
- © Highly experienced board & management
- © Focused strategy
- © Research is targeting specific medical conditions
- © Commercialisation of Cu-Indomethacin is being fast-tracked for regulatory approval

Capital Structure

- ◉ Shares on Issue: 55,671,147
- ◉ Top 20 Shareholders: 54.85%
- ◉ Options on Issue: 20,173,066
- ◉ Top 20 Optionholders: 64.38%

As at 4 December 2006

Our Strategy

“Our aim is to deliver growth and value for shareholders”

Commercialise metallo-NSAIDs for specific cancers & inflammation

Commercialise by joint venture or licensing; fast track to market where possible

Acquire & integrate strategically aligned businesses

Strategically aligned to MTY with existing revenue/cash flow or short term potential and limited use of MTY cash

Acquire/licence/link complementary IP portfolios

Ideally close to clinical trials or close to market; complementary to our pipeline

Protected Patent Portfolio

	Patent Family	Jurisdiction	Status
1	Divalent metal salts of indomethacin	Australia, Canada, Europe, Ireland, NZ, Norway, South Korea, USA, International	Granted
2	Anti-inflammatory compositions	Australia, USA, International	PCT Published 10/05
3	Copper complexes	Australia, USA, International	PCT Published 9/06
4	Methods for treating inflammatory conditions in humans and animals	Australia	PCT Published 9/06
5	Method of treating carcinomas	Australia, International	PCT Published 9/06
6	Methods and compositions for the prophylaxis or treatment of cancers of the skin	Australia International	Pending PCT Published 9/06
7	Methods for prophylaxis or treatment of cardiovascular inflammation	Australia, USA	Pending
8	Methods for prophylaxis or treatment	Australia, USA	Pending

Planned Timeline

Q3 2006

Q4 2006

Q1/Q2 2007

Q2/Q3 2007

Q3/Q4 2007

Select CT managers
Appoint Product
manufacturers

Select capsule
manufacturer
Request pre-
meeting for IND

Conduct
Clinical Study

Prepare & lodge
submission with FDA
& TGA

Registration in USA and
Australia

Conclude Acute
Cardiovascular trial

Announce
results of trial

Investigate 1/2a
Clinical Trial

Conduct Phase 1/a CT
for treatment of acute
CV inflammation

Indicative results of
Sunscreen trial

Early stage
Commercial
discussions

Conclude
Sunscreen trial

Negotiate with
prospective
licensees

Identify and review biotech companies and IP portfolios for potential acquisition


Engage with potential commercial partners

MEDICALTHERAPIES 

Lead Product Development

- © Research is targeting specific medical conditions
- © Copper Indomethacin; the lead compound
- © Copper Indo is targeted as an anti inflammatory in humans
- © Commercialisation of Cu-Indomethacin is being fast-tracked for regulatory approval

Existing Veterinary Use of Copper Indomethacin Drugs




- © We have licensed this drug to Nature Vet for veterinary use and expect growing royalties from the veterinary market
- © Copper Indomethacin has been used as an anti-inflammatory in animals for 5 years
- © Our objective is to take Copper Indomethacin, which has been successfully used in animals, and develop it for use in humans

Development Pipeline

Current lead compounds: Copper/Zinc-indomethacin

	Application	Current or Next steps for MTY R&D	Objective	Ultimate destination for IP Application
1	Anti-Inflammatory	Manufacture of cGMP product and attend initial meetings with TGA/FDA	Registration by Q4 2007	Large global partner – Pharmaceutical company (oral or topical application) cGMP manufacturing for specific market segments (China & India)
2	Pain Management	Proof of concept	Reach Clinical Trials	TGA registration for pain management in palliative care and/or acute/ chronic inflammation
3	Acute cardiovascular inflammation	Pre-clinical trials (Heart Research Institute, Sydney)	Establish proof of concept	
4	Skin Cancer (Therapy)	Pre-clinical Melanoma trials (University of Sydney, melanoma)	Dose Escalation Study Phase I – II	Pharmaceutical company (topical & injectable product)
5	Skin Cancer (Therapy & Prevention)	Pre-clinical Melanoma trials (University of Sydney)	Clinical Trials	Medium to large Health Co (topical application in OTC skin lotions; and/or Rx skin cancer cream/ intra-lesion injection)

Product Roll-out Strategy



Sources: IMS MIDAS Quantum, Jun 2005; Kalorama Information, A Division of MarketResearch.com, Nov 2005

Board & Management

Chairman

Professor Michael Vitale BA PhD MBA

CEO

Mr Malcom Castle, MSc(Hons) MBA MInstP MAICD


Directors

Dr Michael Taverner BAgricSci MAgricSci PhD

Company Secretary

Ian Gilmour FCIS, CA, FAICD, JP(NSW)

Key Partnerships



University of Sydney

Research is carried out under contract by the University of Sydney and is led by

**Professor Peter Lay &
Professor Trevor Hambley**

Auditors

PricewaterhouseCoopers

Lawyers

**Steinepreis Paganin
Middletons**

Patent Attorneys

AdamsPluck

Clinical Study Manager

Novotech

Corporate Advisor

Inteq Limited

2007 Goals

- © Australian TGA registration for Copper Indomethacin (CuIndo) by Q4, 2007
 - licensing and/or manufacture can then begin
- © Two animal trials currently underway
 - skin cancer and acute vascular inflammation
- © Ethics applications for 2007 clinical trials and human pharmacokinetic studies